Ubs Group Ag Grifols Sa Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Grifols Sa stock. As of the latest transaction made, Ubs Group Ag holds 1,061,167 shares of GRFS stock, worth $9.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,061,167

Previous 29,400 3509.41%

Holding current value

$9.37 Million

Previous $196,000 3310.71%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$6.27 - $7.7 $3.03 Million - $3.72 Million	482,497 Added 83.38%	1,061,167 $6.69 Million
Q1 2024 May 13, 2024	BUY	$5.47 - $11.38 $2.79 Million - $5.8 Million	509,819 Added 740.47%	578,670 $3.87 Million
Q4 2023 Feb 09, 2024	SELL	$7.71 - $11.56 $79,867 - $119,750	-10,359 Reduced 13.08%	68,851 $795,000
Q3 2023 Nov 09, 2023	SELL	$8.91 - $10.91 $126,851 - $155,325	-14,237 Reduced 15.24%	79,210 $723,000
Q2 2023 Aug 11, 2023	SELL	$7.14 - $9.29 $217,784 - $283,363	-30,502 Reduced 24.61%	93,447 $855,000
Q1 2023 May 12, 2023	BUY	$6.65 - $10.69 $392,689 - $631,255	59,051 Added 90.99%	123,949 $913,000
Q4 2022 Feb 08, 2023	SELL	$5.96 - $8.53 $136,114 - $194,808	-22,838 Reduced 26.03%	64,898 $551,000
Q3 2022 Nov 10, 2022	SELL	$5.95 - $14.3 $819,814 - $1.97 Million	-137,784 Reduced 61.1%	87,736 $541,000
Q2 2022 Aug 10, 2022	BUY	$10.6 - $13.28 $590,844 - $740,227	55,740 Added 32.83%	225,520 $2.68 Million
Q1 2022 May 16, 2022	BUY	$10.37 - $12.73 $319,499 - $392,211	30,810 Added 22.17%	169,780 $1.98 Million
Q4 2021 Feb 14, 2022	SELL	$10.21 - $15.27 $795,277 - $1.19 Million	-77,892 Reduced 35.92%	138,970 $1.56 Million
Q3 2021 Nov 15, 2021	BUY	$14.07 - $17.3 $697,365 - $857,457	49,564 Added 29.63%	216,862 $3.17 Million
Q2 2021 Aug 13, 2021	SELL	$16.62 - $18.94 $66.1 Million - $75.4 Million	-3,978,989 Reduced 95.97%	167,298 $2.9 Million
Q1 2021 May 12, 2021	SELL	$15.15 - $19.78 $27.4 Million - $35.8 Million	-1,808,064 Reduced 30.37%	4,146,287 $71.7 Million
Q4 2020 Feb 11, 2021	BUY	$16.86 - $19.67 $70.6 Million - $82.4 Million	4,189,882 Added 237.46%	5,954,351 $110 Million
Q3 2020 Nov 12, 2020	BUY	$15.4 - $20.16 $25.1 Million - $32.8 Million	1,626,881 Added 1182.43%	1,764,469 $30.6 Million
Q2 2020 Jul 31, 2020	BUY	$18.24 - $21.45 $1.73 Million - $2.04 Million	95,041 Added 223.38%	137,588 $2.51 Million
Q1 2020 May 01, 2020	SELL	$16.28 - $25.63 $26.5 Million - $41.7 Million	-1,627,517 Reduced 97.45%	42,547 $857,000
Q4 2019 Feb 14, 2020	SELL	$19.57 - $23.52 $3.4 Million - $4.09 Million	-173,836 Reduced 9.43%	1,670,064 $38.9 Million
Q3 2019 Nov 14, 2019	BUY	$19.85 - $22.76 $10.4 Million - $11.9 Million	521,739 Added 39.46%	1,843,900 $37 Million
Q2 2019 Aug 14, 2019	BUY	$17.59 - $21.1 $4.94 Million - $5.92 Million	280,695 Added 26.95%	1,322,161 $27.9 Million
Q1 2019 May 14, 2019	BUY	$18.01 - $20.11 $1.36 Million - $1.52 Million	75,663 Added 7.83%	1,041,466 $20.9 Million
Q4 2018 Feb 14, 2019	SELL	$17.44 - $21.53 $7.11 Million - $8.78 Million	-407,831 Reduced 29.69%	965,803 $17.7 Million
Q3 2018 Nov 14, 2018	BUY	$19.97 - $21.96 $3.12 Million - $3.43 Million	156,410 Added 12.85%	1,373,634 $29.4 Million
Q2 2018 Aug 14, 2018	BUY	$20.16 - $24.68 $23 Million - $28.1 Million	1,139,980 Added 1475.82%	1,217,224 $26.2 Million
Q1 2018 May 15, 2018	BUY	$20.31 - $24.95 $927,882 - $1.14 Million	45,686 Added 144.77%	77,244 $1.64 Million
Q4 2017 Feb 14, 2018	SELL	$20.99 - $23.89 $7.56 Million - $8.61 Million	-360,378 Reduced 91.95%	31,558 $723,000
Q3 2017 Nov 14, 2017	BUY	$20.07 - $21.89 $7.46 Million - $8.14 Million	371,890 Added 1855.18%	391,936 $8.58 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-165,012 Reduced 89.17%	20,046 $424,000
Q1 2017 Nov 14, 2017	BUY	N/A	185,058	185,058 $3.49 Million

Others Institutions Holding GRFS

# of Institutions

147

Shares Held

151M

Call Options Held

2.38M

Put Options Held

662K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.99B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account